查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1869757

药物重定位市场规模、份额和趋势分析报告：按治疗领域、药物类型、最终用途、地区和细分市场预测（2025-2033 年）

Drug Repurposing Market Size, Share & Trends Analysis Report By Disease Area (Oncology, Neurology Disorders, Infectious Diseases, Cardiovascular Conditions, Metabolic Disorders), By Drug Type, By End Use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

药物重定位市场摘要

2024年全球药物重定位市场规模估计为329.6亿美元，预计2033年将达474亿美元。

预计从2025年到2033年，该市场将以4.12%的复合年增长率成长。由于该市场有潜力为製药公司提供经济高效且省时的解决方案，因此备受关注。

推动这一增长的关键因素在于能够利用已确立安全性特征的现有药物，这显着减少了耗时的临床前试验和早期临床开发的需求。例如，2023年9月，美国食品药物管理局（FDA）批准了Empagliflozin（Jardiance），这是一种最初为治疗第2型糖尿病而开发的药物，用于治疗有进展核准的成人慢性肾臟病（CKD），无论是否患有糖尿病。

由勃林格殷格翰和礼来公司联合研发的Empagliflozin）在临床试验中展现出令人鼓舞的结果，可降低慢性肾臟病（CKD）患者肾功能下降、肾衰竭、心血管死亡和心臟衰竭住院的风险。该药物最初核准用于治疗第2型糖尿病，此次核准使其应用范围扩展至糖尿病治疗之外，也反映了将现有药物用于治疗选择有限的疾病日益增长的趋势。这项进展凸显了人们对药物再利用的日益增长的支持，以及利用现有药物开发新适应症的显着益处。

此外，慢性病和罕见病患疾病率的不断上升是仿单标示外使用的主要因素。例如，2022年12月，FDA核准Cariprazine（商品名Vraylar）作为辅助治疗药物，用于治疗对抗抗忧郁症疗效不佳的成人重度忧郁症（MDD）。Cariprazine最初由吉瑞製药（Gedeon Richter）研发，并于2015年首次核准FDA批准，用于治疗思觉失调症和I型双相情感障碍。艾伯维（AbbVie）于2020年透过收购艾尔建（Allergan）获得了Cariprazine的权益。此次核准Vraylar获准的第四项适应症，也印证了将现有药物重新用于治疗治疗选择有限的疾病日益增长的趋势。

2023年3月，美国食品药物管理局（FDA）批准了最初用于核准活化磷脂-3-激酶Delta综合征（APDS）的药物leniolisib（商品名Joenja），用于治疗活化PI3Kδ综合征，这是一种罕见的免疫疾病。 Leniolisib是一种选择性PI3Kδ酶抑制剂，PI3Kδ酶在免疫细胞功能中发挥关键作用。 Leniolisib的核准凸显了将现有药物重新用于治疗罕见疾病和孤儿病的趋势日益增长，因为在这些疾病中，开发新药既耗时又难以实现成本效益。这项策略性倡议表明，人们越来越支持药物重新用于治疗方法的开发。

辉瑞一直积极致力于透过药物再利用来推广前列腺癌的治疗。 2021年7月，辉瑞与Albinus Therapeutics达成一项全球共同开发契约，共同开发和商业化ARV-471，这是一种口服PROTAC®（蛋白水解靶向嵌合体）雌激素受体蛋白降解剂。此次合作旨在利用现有疗法来应对复杂且治疗不足的癌症，这与辉瑞拓展其肿瘤产品组合的整体策略一致。此外，2024年4月，Albinus Therapeutics与诺华达成一项许可和资产出售协议，共同开发和商业化ARV-766，这是一种正在开发用于治疗前列腺癌的第二代雄激素受体降解剂。该协议总价值超过10亿美元，显示各方对透过现有药物再利用来拓展前列腺癌治疗方案的兴趣和投资日益增长。

2025年1月，拜耳向美国食品药物管理局（FDA）提交了一份补充新药申请（sNDA），旨在扩大凯伦迪亚（Kelendia）的核准，使其涵盖左心室心臟衰竭（ HF）患者，包括轻度射血分数降低的心臟衰竭患者的心臟衰竭和新药认证患者的心臟衰竭（HFpEF）。 FDA受理了该申请并授予优先审查资格。 2025年7月14日，FDA在完成对该sNDA的优先审查后，核准了这项新适应症。

目录

第一章调查方法和范围

第二章执行摘要

3. 药物重定位市场变数、趋势与范围

  • 市场体系展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 商业环境分析
    • 产业分析—波特五力分析
    • PESTLE分析
    • 管道分析

第四章：药物重定位市场：依治疗领域分類的业务分析

  • 按治疗领域分類的市场份额，2024 年和 2033 年
  • 治疗领域细分仪表板
  • 全球药物重定位市场规模、预测与趋势分析（按治疗领域划分，2021-2033 年）
  • 肿瘤学
  • 神经系统疾病
  • 感染疾病
  • 心血管疾病
  • 代谢紊乱
  • 其他治疗领域

第五章 药物重定位市场：依药物类型分類的业务分析

  • 按药物类型分類的市场份额，2024 年和 2033 年
  • 药物类型细分仪表板
  • 全球药物重定位市场规模、预测与趋势分析（按药物类型划分，2021-2033 年）
  • 传统小分子
  • 生技药品和胜肽类药物

第六章 药品再利用市场：依最终用途分類的业务分析

  • 按最终用途分類的市场份额，2024 年和 2033 年
  • 最终用户细分仪表板
  • 全球药物重定位市场规模、预测与趋势分析（按最终用途划分，2021-2033 年）
  • 生物製药和製药公司
  • 临床研究机构（CRO）
  • 大学和研究机构

第七章 药物重定位市场：区域估算与趋势分析

  • 2024 年及 2033 年区域市占率分析
  • 区域市场概览
  • 全球药物重定位市场规模及预测趋势分析（2021-2033）：
  • 北美洲
    • 按国家/地区划分，2021-2033 年
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争情势

  • 参与企业概况
  • 企业市场分析
  • 公司分类
  • 策略规划
  • 公司简介
    • Eli Lilly and Company
    • Pfizer Inc.
    • Roche Holding AG
    • Novartis AG
    • Bayer AG
    • GSK plc
    • Amgen Inc.
    • Biogen Inc.
    • Teva Pharmaceutical
    • Vertex Pharmaceuticals
Product Code: GVR-4-68040-760-1

Drug Repurposing Market Summary

The global drug repurposing market size was estimated at USD 32.96 billion in 2024 and is projected to reach USD 47.40 billion by 2033, growing at a CAGR of 4.12% from 2025 to 2033. The market has gained significant traction, driven by the potential to offer both cost-effective and time-efficient solutions for pharmaceutical companies.

A critical driver of this growth is the opportunity to leverage existing drugs with well-established safety profiles, significantly reducing the need for lengthy preclinical trials and early-phase clinical development. For instance, in September 2023, the FDA approved empagliflozin (brand name Jardiance), a medication originally developed for type 2 diabetes, for the treatment of chronic kidney disease (CKD) in adults at risk of progression, regardless of diabetes status.

Empagliflozin, developed by Boehringer Ingelheim and Eli Lilly, has shown promising results in clinical trials for reducing the risk of kidney function decline, kidney failure, cardiovascular death, and hospitalization for heart failure in CKD patients. While initially approved for type 2 diabetes, this approval extends its potential beyond diabetes management, demonstrating the growing trend of repurposing existing drugs for conditions with limited treatment options. This move highlights the increasing support for drug repurposing efforts and the significant benefits of leveraging established medications for new therapeutic indications.

Furthermore, the rising prevalence of chronic and rare diseases has significantly contributed to the push for repurposed drugs. For example, in December 2022, the FDA approved cariprazine (brand name Vraylar) as an adjunctive treatment for major depressive disorder (MDD) in adults who have had an inadequate response to antidepressant therapy. Cariprazine was originally developed by Gedeon Richter and was first approved by the FDA in 2015 for the treatment of schizophrenia and bipolar I disorder. AbbVie acquired the rights to cariprazine through its acquisition of Allergan in 2020. This approval marks the fourth indication for Vraylar, underscoring the growing trend of repurposing existing medications to address conditions with limited treatment options.

In March 2023, the FDA approved leniolisib (brand name Joenja), a medication originally developed for activated phosphoinositide 3-kinase delta syndrome (APDS), for the treatment of activated PI3K delta syndrome, a rare immune disorder. Leniolisib is a selective inhibitor of the PI3Kδ enzyme, which plays a crucial role in immune cell function. The approval of leniolisib highlights the growing trend of repurposing existing drugs to address rare and orphan diseases, where the development of new drugs can be cost-prohibitive and time-consuming. This strategic move underscores the increasing support for drug repurposing efforts to encourage the development of treatments for conditions with limited therapeutic options.

In drug repurposing, Pfizer has been actively engaged in advancing treatments for prostate cancer. In July 2021, Pfizer entered into a global collaboration with Arvinas to co-develop and co-commercialize ARV-471, an investigational oral PROTAC(R) (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. This partnership aims to leverage existing treatments to address complex and underserved cancers, aligning with Pfizer's broader strategy to expand its oncology portfolio. Additionally, in April 2024, Arvinas entered into a separate licensing and asset-sale agreement with Novartis, valued at over USD 1 billion, for the development and commercialization of ARV-766, a second-generation androgen receptor degrader for prostate cancer. This move underscores the growing interest and investment in repurposing existing drugs to enhance treatment options for prostate cancer patients.

In January 2025, Bayer submitted an sNDA to the U.S. Food and Drug Administration (FDA) seeking approval for Kerendia to treat adult patients with heart failure (HF) and a left ventricular ejection fraction (LVEF) of >=40%, including both mildly reduced ejection fraction (HFmrEF) and preserved ejection fraction (HFpEF). The FDA accepted the application and granted Priority Review designation. The FDA approved this new indication on July 14, 2025, following the agency's Priority Review of its supplemental New Drug Application (sNDA

Global Drug Repurposing Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global drug repurposing market report based on Disease Area, drug type, end use, and region :

  • Disease Area Outlook (Revenue, USD Million, 2021 - 2033)
  • Oncology
  • Neurology Disorders
  • Infectious Diseases
  • Cardiovascular Conditions
  • Metabolic Disorders
  • Others Therapeutic Areas
  • Drug Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Conventional Small Molecules
  • Biologics and Peptide-based Drugs
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Biopharmaceutical & Pharmaceutical Companies
  • Clinical Research Organizations (CROs)
  • Universities & Research Institutions
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Disease Area
    • 1.2.2. Drug Type
    • 1.2.3. End Use
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Drug Repurposing Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis

Chapter 4. Drug Repurposing Market: Disease Area Business Analysis

  • 4.1. Disease Area Market Share, 2024 & 2033
  • 4.2. Disease Area Segment Dashboard
  • 4.3. Global Drug Repurposing Market Size & Forecasts and Trend Analysis, by Disease Area, 2021 to 2033 (USD Million)
  • 4.4. Oncology
    • 4.4.1. Oncology Market, 2021 - 2033 (USD Million)
  • 4.5. Neurology Disorders
    • 4.5.1. Neurology Disorders Market, 2021 - 2033 (USD Million)
  • 4.6. Infectious Diseases
    • 4.6.1. Infectious Diseases Market, 2021 - 2033 (USD Million)
  • 4.7. Cardiovascular Conditions
    • 4.7.1. Cardiovascular Conditions Market, 2021 - 2033 (USD Million)
  • 4.8. Metabolic Disorders
    • 4.8.1. Metabolic Disorders Market, 2021 - 2033 (USD Million)
  • 4.9. Others Therapeutic Areas
    • 4.9.1. Others Therapeutic Areas Market, 2021 - 2033 (USD Million)

Chapter 5. Drug Repurposing Market: Drug Type Business Analysis

  • 5.1. Drug Type Market Share, 2024 & 2033
  • 5.2. Drug Type Segment Dashboard
  • 5.3. Global Drug Repurposing Market Size & Forecasts and Trend Analysis, by Drug Type, 2021 to 2033 (USD Million)
  • 5.4. Conventional Small Molecules
    • 5.4.1. Conventional Small Molecules Market, 2021 - 2033 (USD Million)
  • 5.5. Biologics and Peptide-based Drugs
    • 5.5.1. Biologics and Peptide-based Drugs Market, 2021 - 2033 (USD Million)

Chapter 6. Drug Repurposing Market: End Use Business Analysis

  • 6.1. End Use Market Share, 2024 & 2033
  • 6.2. End Use Segment Dashboard
  • 6.3. Global Drug Repurposing Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (USD Million)
  • 6.4. Biopharmaceutical & Pharmaceutical Companies
    • 6.4.1. Biopharmaceutical & Pharmaceutical Companies Market, 2021 - 2033 (USD Million)
  • 6.5. Clinical Research Organizations (CROs)
    • 6.5.1. Clinical Research Organizations (CROs) Market, 2021 - 2033 (USD Million)
  • 6.6. Universities & Research Institutions
    • 6.6.1. Universities & Research Institutions Market, 2021 - 2033 (USD Million)

Chapter 7. Drug Repurposing Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2033
  • 7.2. Regional Market Dashboard
  • 7.3. Global Drug Repurposing Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 7.4. North America
    • 7.4.1. North America Drug Repurposing Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Regulatory Framework
      • 7.4.2.3. Reimbursement Framework
      • 7.4.2.4. U.S. Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Regulatory Framework
      • 7.4.3.3. Reimbursement Framework
      • 7.4.3.4. U.S. Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Regulatory Framework
      • 7.4.4.3. Reimbursement Framework
      • 7.4.4.4. Mexico Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Regulatory Framework
      • 7.5.2.3. Reimbursement Framework
      • 7.5.2.4. UK Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Regulatory Framework
      • 7.5.3.3. Reimbursement Framework
      • 7.5.3.4. Germany Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Regulatory Framework
      • 7.5.4.3. Reimbursement Framework
      • 7.5.4.4. France Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Regulatory Framework
      • 7.5.5.3. Reimbursement Framework
      • 7.5.5.4. Italy Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Regulatory Framework
      • 7.5.6.3. Reimbursement Framework
      • 7.5.6.4. Spain Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Regulatory Framework
      • 7.5.7.3. Reimbursement Framework
      • 7.5.7.4. Denmark Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Regulatory Framework
      • 7.5.8.3. Reimbursement Framework
      • 7.5.8.4. Sweden Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Regulatory Framework
      • 7.5.9.3. Reimbursement Framework
      • 7.5.9.4. Norway Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Regulatory Framework
      • 7.6.2.3. Reimbursement Framework
      • 7.6.2.4. Japan Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Target Disease Prevalence
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Framework
      • 7.6.3.5. China Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Regulatory Framework
      • 7.6.4.3. Reimbursement Framework
      • 7.6.4.4. India Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Regulatory Framework
      • 7.6.5.3. Reimbursement Framework
      • 7.6.5.4. Australia Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Regulatory Framework
      • 7.6.6.3. Reimbursement Framework
      • 7.6.6.4. South Korea Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Regulatory Framework
      • 7.6.7.3. Reimbursement Framework
      • 7.6.7.4. Thailand Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Regulatory Framework
      • 7.7.2.3. Reimbursement Framework
      • 7.7.2.4. Japan Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Regulatory Framework
      • 7.7.3.3. Reimbursement Framework
      • 7.7.3.4. China Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8. Middle East and Africa
    • 7.8.1. Middle East and Africa Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Regulatory Framework
      • 7.8.2.3. Reimbursement Framework
      • 7.8.2.4. South Africa Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Regulatory Framework
      • 7.8.3.3. Reimbursement Framework
      • 7.8.3.4. Saudi Arabia Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Regulatory Framework
      • 7.8.4.3. Reimbursement Framework
      • 7.8.4.4. UAE Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Regulatory Framework
      • 7.8.5.3. Reimbursement Framework
      • 7.8.5.4. Kuwait Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Eli Lilly and Company
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Pfizer Inc.
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Roche Holding AG
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Novartis AG
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Bayer AG
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. GSK plc
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Amgen Inc.
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Biogen Inc.
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Teva Pharmaceutical
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Vertex Pharmaceuticals
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global drug repurposing market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 5 Global drug repurposing market, by drug type , 2021 - 2033 (USD Million)
  • Table 6 Global drug repurposing market, by end use , 2021 - 2033 (USD Million)
  • Table 7 North America drug repurposing market, by country, 2021 - 2033 (USD Million)
  • Table 8 North America drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 9 North America drug repurposing market, by drug type , 2021 - 2033 (USD Million)
  • Table 10 North America drug repurposing market, by end use , 2021 - 2033 (USD Million)
  • Table 11 U.S drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 12 U.S drug repurposing market, by drug type , 2021 - 2033 (USD Million)
  • Table 13 U.S drug repurposing market, by end use , 2021 - 2033 (USD Million)
  • Table 14 Canada drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 15 Canada drug repurposing market, by drug type , 2021 - 2033 (USD Million)
  • Table 16 Canada drug repurposing market, by end use , 2021 - 2033 (USD Million)
  • Table 17 Mexico drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 18 Mexico drug repurposing market, by drug type , 2021 - 2033 (USD Million)
  • Table 19 Mexico drug repurposing market, by end use , 2021 - 2033 (USD Million)
  • Table 20 Europe drug repurposing market, by country, 2021 - 2033 (USD Million)
  • Table 21 Europe drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 22 Europe drug repurposing market, by drug type , 2021 - 2033 (USD Million)
  • Table 23 Europe drug repurposing market, by end use , 2021 - 2033 (USD Million)
  • Table 24 UK drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 25 UK drug repurposing market, by drug type , 2021 - 2033 (USD Million)
  • Table 26 UK drug repurposing market, by end use , 2021 - 2033 (USD Million)
  • Table 27 Germany drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 28 Germany drug repurposing market, by drug type , 2021 - 2033 (USD Million)
  • Table 29 Germany drug repurposing market, by end use , 2021 - 2033 (USD Million)
  • Table 30 France drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 31 France drug repurposing market, by drug type , 2021 - 2033 (USD Million)
  • Table 32 France drug repurposing market, by end use , 2021 - 2033 (USD Million)
  • Table 33 Italy drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 34 Italy drug repurposing market, by drug type , 2021 - 2033 (USD Million)
  • Table 35 Italy drug repurposing market, by end use , 2021 - 2033 (USD Million)
  • Table 36 Spain drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 37 Spain drug repurposing market, by drug type , 2021 - 2033 (USD Million)
  • Table 38 Spain drug repurposing market, by end use , 2021 - 2033 (USD Million)
  • Table 39 Norway drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 40 Norway drug repurposing market, by drug type , 2021 - 2033 (USD Million)
  • Table 41 Norway drug repurposing market, by end use , 2021 - 2033 (USD Million)
  • Table 42 Denmark drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 43 Denmark drug repurposing market, by drug type , 2021 - 2033 (USD Million)
  • Table 44 Denmark drug repurposing market, by end use , 2021 - 2033 (USD Million)
  • Table 45 Sweden drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 46 Sweden drug repurposing market, by drug type , 2021 - 2033 (USD Million)
  • Table 47 Sweden drug repurposing market, by end use , 2021 - 2033 (USD Million)
  • Table 48 Asia Pacific drug repurposing market, by country, 2021 - 2033 (USD Million)
  • Table 49 Asia Pacific drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 50 Asia Pacific drug repurposing market, by drug type , 2021-2033, (USD
  • Table 51 Asia Pacific drug repurposing market, by end use , 2021-2033, (USD Million)
  • Table 52 Japan drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 52 Japan drug repurposing market, by drug type , 2021 - 2033 (USD Million)
  • Table 54 Japan drug repurposing market, by end use , 2021 - 2033 (USD Million)
  • Table 55 China drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 56 China drug repurposing market, by drug type , 2021 - 2033 (USD Million)
  • Table 57 China drug repurposing market, by end use , 2021 - 2033 (USD Million)
  • Table 58 India drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 69 India drug repurposing market, by drug type , 2021 - 2033 (USD Million)
  • Table 70 India drug repurposing market, by end use , 2021 - 2033 (USD Million)
  • Table 71 Australia drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 72 Australia drug repurposing market, by drug type , 2021 - 2033 (USD Million)
  • Table 73 Australia drug repurposing market, by end use , 2021 - 2033 (USD Million)
  • Table 74 South Korea drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 75 South Korea drug repurposing market, by drug type , 2021 - 2033 (USD Million)
  • Table 76 South Korea drug repurposing market, by end use , 2021 - 2033 (USD Million)
  • Table 77 Thailand drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 78 Thailand drug repurposing market, by drug type , 2021 - 2033 (USD Million)
  • Table 89 Thailand drug repurposing market, by end use , 2021 - 2033 (USD Million)
  • Table 80 Latin America drug repurposing market, by country, 2021 - 2033 (USD Million)
  • Table 81 Latin America drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 82 Latin America drug repurposing market, by drug type , 2021 - 2033 (USD Million)
  • Table 83 Latin America drug repurposing market, by end use , 2021 - 2033 (USD Million)
  • Table 84 Brazil drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 85 Brazil drug repurposing market, by drug type , 2021 - 2033 (USD Million)
  • Table 86 Brazil drug repurposing market, by end use , 2021 - 2033 (USD Million)
  • Table 87 Argentina drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 88 Argentina drug repurposing market, by drug type , 2021 - 2033 (USD Million)
  • Table 89 Argentina drug repurposing market, by end use , 2021 - 2033 (USD Million)
  • Table 90 Middle East & Africa Drug repurposing market, by country, 2021 - 2033 (USD Million)
  • Table 91 Middle East & Africa drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 92 Middle East & Africa drug repurposing market, by drug type , 2021 - 2033 (USD Million)
  • Table 93 Middle East & Africa drug repurposing market, by end use , 2021 - 2033 (USD Million)
  • Table 94 South Africa drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 95 South Africa drug repurposing market, by drug type , 2021 - 2033 (USD Million)
  • Table 96 South Africa drug repurposing market, by end use , 2021 - 2033 (USD Million)
  • Table 97 Saudi Arabia drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 98 Saudi Arabia drug repurposing market, by drug type , 2021 - 2033 (USD Million)
  • Table 99 Saudi Arabia drug repurposing market, by end use , 2021 - 2033 (USD Million)
  • Table 100 UAE drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 101 UAE drug repurposing market, by drug type , 2021 - 2033 (USD Million)
  • Table 102 UAE drug repurposing market, by end use , 2021 - 2033 (USD Million)
  • Table 103 Kuwait drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 104 Kuwait drug repurposing market, by drug type , 2021 - 2033 (USD Million)
  • Table 105 Kuwait drug repurposing market, by end use , 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Drug repurposing market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and disease area outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Drug repurposing market dynamics
  • Fig. 12 Drug repurposing market: Porter's five forces analysis
  • Fig. 13 Drug repurposing market: PESTLE analysis
  • Fig. 14 Oncology market, 2021 - 2033 (USD Million)
  • Fig. 15 Neurology Disorders market, 2021 - 2033 (USD Million)
  • Fig. 16 Infectious Diseases market, 2021 - 2033 (USD Million)
  • Fig. 17 Cardiovascular Conditions market, 2021 - 2033 (USD Million)
  • Fig. 18 Metabolic Disorders market, 2021 - 2033 (USD Million)
  • Fig. 19 Others Therapeutic Areas market, 2021 - 2033 (USD Million)
  • Fig. 20 Drug Type market, 2021 - 2033 (USD Million)
  • Fig. 21 Conventional Small Molecules market, 2021 - 2033 (USD Million)
  • Fig. 22 Biologics and Peptide-based Drugs market, 2021 - 2033 (USD Million)
  • Fig. 23 End Use market, 2021 - 2033 (USD Million)
  • Fig. 24 Biopharmaceutical & Pharmaceutical Companies market, 2021 - 2033 (USD Million)
  • Fig. 25 Clinical Research Organizations (CROs) market, 2021 - 2033 (USD Million)
  • Fig. 26 Universities & Research Institutions market, 2021 - 2033 (USD Million)
  • Fig. 27 Drug repurposing market revenue, by region
  • Fig. 28 Regional marketplace: Key takeaways
  • Fig. 29 North America drug repurposing market, 2021 - 2033 (USD Million)
  • Fig. 30 U.S. country dynamics
  • Fig. 31 U.S. drug repurposing market, 2021 - 2033 (USD Million)
  • Fig. 32 Canada country dynamics
  • Fig. 33 Canada drug repurposing market, 2021 - 2033 (USD Million)
  • Fig. 34 Mexico country dynamics
  • Fig. 35 Mexico drug repurposing market, 2021 - 2033 (USD Million)
  • Fig. 36 Europe drug repurposing market, 2021 - 2033 (USD Million)
  • Fig. 37 UK country dynamics
  • Fig. 38 UK drug repurposing market, 2021 - 2033 (USD Million)
  • Fig. 39 Germany country dynamics
  • Fig. 40 Germany drug repurposing market, 2021 - 2033 (USD Million)
  • Fig. 41 France country dynamics
  • Fig. 42 France drug repurposing market, 2021 - 2033 (USD Million)
  • Fig. 43 Italy country dynamics
  • Fig. 44 Italy drug repurposing market, 2021 - 2033 (USD Million)
  • Fig. 45 Spain country dynamics
  • Fig. 46 Spain drug repurposing market, 2021 - 2033 (USD Million)
  • Fig. 47 Norway country dynamics
  • Fig. 48 Norway drug repurposing market, 2021 - 2033 (USD Million)
  • Fig. 49 Sweden country dynamics
  • Fig. 50 Sweden drug repurposing market, 2021 - 2033 (USD Million)
  • Fig. 51 Denmark country dynamics
  • Fig. 52 Denmark drug repurposing market, 2021 - 2033 (USD Million)
  • Fig. 53 Asia Pacific drug repurposing market, 2021 - 2033 (USD Million)
  • Fig. 54 Japan country dynamics
  • Fig. 55 Japan drug repurposing market, 2021 - 2033 (USD Million)
  • Fig. 56 China country dynamics
  • Fig. 57 China drug repurposing market, 2021 - 2033 (USD Million)
  • Fig. 58 India country dynamics
  • Fig. 59 India drug repurposing market, 2021 - 2033 (USD Million)
  • Fig. 60 Australia country dynamics
  • Fig. 61 Australia drug repurposing market, 2021 - 2033 (USD Million)
  • Fig. 62 South Korea country dynamics
  • Fig. 63 South Korea drug repurposing market, 2021 - 2033 (USD Million)
  • Fig. 64 Thailand country dynamics
  • Fig. 65 Thailand drug repurposing market, 2021 - 2033 (USD Million)
  • Fig. 66 Latin America drug repurposing market, 2021 - 2033 (USD Million)
  • Fig. 67 Brazil country dynamics
  • Fig. 68 Brazil drug repurposing market, 2021 - 2033 (USD Million)
  • Fig. 69 Argentina country dynamics
  • Fig. 70 Argentina drug repurposing market, 2021 - 2033 (USD Million)
  • Fig. 71 Middle East and Africa drug repurposing market, 2021 - 2033 (USD Million)
  • Fig. 72 South Africa country dynamics
  • Fig. 73 South Africa drug repurposing market, 2021 - 2033 (USD Million)
  • Fig. 74 Saudi Arabia country dynamics
  • Fig. 75 Saudi Arabia drug repurposing market, 2021 - 2033 (USD Million)
  • Fig. 76 UAE country dynamics
  • Fig. 77 UAE drug repurposing market, 2021 - 2033 (USD Million)
  • Fig. 78 Kuwait country dynamics
  • Fig. 79 Kuwait drug repurposing market, 2021 - 2033 (USD Million)
  • Fig. 80 Company categorization
  • Fig. 81 Company market position analysis
  • Fig. 82 Strategic framework